Nomogram for Astigmatism Correction of KLEx
Nomogram Optimization for Astigmatism Precision Correction of Corneal Refractive Correction
1 other identifier
interventional
100
1 country
1
Brief Summary
The goal of this clinical trial is to learn if nomogram could promote treatment outcomes in astigmatism correction. The main question it aims to answer is: does the nomogram could promote treatment outcomes in astigmatism correction? If there is a comparison group: Researchers will compare non-nomogram adopted to see if the outcome acceptable. Participants will ask to complete 3-month follow-up of manifest refraction and visual acuity test.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 18, 2025
CompletedFirst Submitted
Initial submission to the registry
May 18, 2026
CompletedFirst Posted
Study publicly available on registry
May 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
May 22, 2026
May 1, 2026
1.9 years
May 18, 2026
May 18, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
residual astigmstism
3 months
Secondary Outcomes (1)
visual acuity
3 months
Study Arms (2)
nomogram group
EXPERIMENTALastigmatism was corrected with nomogram adjustment
control group
NO INTERVENTIONastigmatism was corrected without nomogram adjustment
Interventions
Eligibility Criteria
You may qualify if:
- age ≥18 years; preoperative sphere -0.50 D to -10.00 D; preoperative cylinder -1.50 D to -5.00 D; stable refraction (±0.50 D) for 1 year; normal corneal topography; central corneal thickness \>500 μm or predicted residual stromal bed \>280 μm; intraocular pressure \<21 mmHg
You may not qualify if:
- ocular or systematic disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, 300000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 18, 2026
First Posted
May 22, 2026
Study Start
February 18, 2025
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2027
Last Updated
May 22, 2026
Record last verified: 2026-05